TY - JOUR AU - Chandrasekar, T. AU - Yang, J. C. AU - Gao, A. C. AU - Evans, C. P. PY - 2015 DA - 2015// TI - Mechanisms of resistance in castration-resistant prostate cancer (CRPC) JO - Transl Androl Urol VL - 4 ID - Chandrasekar2015 ER - TY - JOUR AU - Hong, J. H. AU - Kim, I. Y. PY - 2014 DA - 2014// TI - Nonmetastatic castration-resistant prostate cancer JO - Korean J Urol VL - 55 UR - https://doi.org/10.4111/kju.2014.55.3.153 DO - 10.4111/kju.2014.55.3.153 ID - Hong2014 ER - TY - JOUR AU - Elishmereni, M. AU - Kheifetz, Y. AU - Shukrun, I. AU - Bevan, G. H. AU - Nandy, D. AU - McKenzie, K. M. PY - 2016 DA - 2016// TI - Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data JO - Prostate VL - 76 UR - https://doi.org/10.1002/pros.23099 DO - 10.1002/pros.23099 ID - Elishmereni2016 ER - TY - JOUR AU - Fowler, J. E. AU - Whitmore, W. F. PY - 1982 DA - 1982// TI - Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer JO - Cancer VL - 49 UR - https://doi.org/3.0.CO;2-G DO - 3.0.CO;2-G ID - Fowler1982 ER - TY - JOUR AU - Matzkin, H. AU - Eber, P. AU - Todd, B. AU - van der Zwaag, R. AU - Soloway, M. S. PY - 1992 DA - 1992// TI - Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer JO - Cancer VL - 70 UR - https://doi.org/3.0.CO;2-2 DO - 3.0.CO;2-2 ID - Matzkin1992 ER - TY - JOUR AU - Arai, Y. AU - Yoshiki, T. AU - Yoshida, O. PY - 1990 DA - 1990// TI - Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer JO - J Urol VL - 144 UR - https://doi.org/10.1016/S0022-5347(17)39757-4 DO - 10.1016/S0022-5347(17)39757-4 ID - Arai1990 ER - TY - JOUR AU - Lin, G. W. AU - Yao, X. D. AU - Zhang, S. L. AU - Dai, B. AU - Ma, C. G. AU - Zhang, H. L. PY - 2009 DA - 2009// TI - Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients JO - Asian J Androl VL - 11 UR - https://doi.org/10.1038/aja.2008.36 DO - 10.1038/aja.2008.36 ID - Lin2009 ER - TY - JOUR AU - D'Amico, A. V. AU - McLeod, D. G. AU - Carroll, P. R. AU - Cullen, J. AU - Chen, M. H. PY - 2007 DA - 2007// TI - Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality JO - Cancer VL - 109 UR - https://doi.org/10.1002/cncr.22550 DO - 10.1002/cncr.22550 ID - D'Amico2007 ER - TY - JOUR AU - Sasaki, T. AU - Onishi, T. AU - Hoshina, A. PY - 2011 DA - 2011// TI - Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis JO - Prostate Cancer Prostatic Dis VL - 14 UR - https://doi.org/10.1038/pcan.2011.14 DO - 10.1038/pcan.2011.14 ID - Sasaki2011 ER - TY - JOUR AU - Kim, M. AU - Lee, J. AU - Jeong, C. W. AU - Ku, J. H. AU - Kim, H. H. AU - Kwak, C. PY - 2015 DA - 2015// TI - Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer JO - Urol Oncol VL - 33 UR - https://doi.org/10.1016/j.urolonc.2015.01.017 DO - 10.1016/j.urolonc.2015.01.017 ID - Kim2015 ER - TY - JOUR AU - Zilli, T. AU - Dal Pra, A. AU - Kountouri, M. AU - Miralbell, R. PY - 2016 DA - 2016// TI - Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: a systematic review of the literature JO - Cancer Treat Rev VL - 46 UR - https://doi.org/10.1016/j.ctrv.2016.03.016 DO - 10.1016/j.ctrv.2016.03.016 ID - Zilli2016 ER - TY - JOUR AU - Armstrong, A. J. AU - Eisenberger, M. A. AU - Halabi, S. AU - Oudard, S. AU - Nanus, D. M. AU - Petrylak, D. P. PY - 2012 DA - 2012// TI - Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer JO - Eur Urol VL - 61 UR - https://doi.org/10.1016/j.eururo.2011.11.009 DO - 10.1016/j.eururo.2011.11.009 ID - Armstrong2012 ER - TY - JOUR AU - Banu, E. AU - Banu, A. AU - Medioni, J. AU - Levy, E. AU - Thiounn, N. AU - Mejean, A. PY - 2007 DA - 2007// TI - Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria JO - Prostate VL - 67 UR - https://doi.org/10.1002/pros.20627 DO - 10.1002/pros.20627 ID - Banu2007 ER - TY - JOUR AU - Park, Y. H. AU - Hwang, I. S. AU - Jeong, C. W. AU - Kim, H. H. AU - Lee, S. E. AU - Kwak, C. PY - 2009 DA - 2009// TI - Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer JO - J Urol VL - 181 UR - https://doi.org/10.1016/j.juro.2009.01.104 DO - 10.1016/j.juro.2009.01.104 ID - Park2009 ER - TY - JOUR AU - Tomioka, A. AU - Tanaka, N. AU - Yoshikawa, M. AU - Miyake, M. AU - Anai, S. AU - Chihara, Y. PY - 2014 DA - 2014// TI - Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer JO - BMC Urol VL - 14 UR - https://doi.org/10.1186/1471-2490-14-33 DO - 10.1186/1471-2490-14-33 ID - Tomioka2014 ER - TY - JOUR AU - Choueiri, T. K. AU - Xie, W. AU - D'Amico, A. V. AU - Ross, R. W. AU - Hu, J. C. AU - Pomerantz, M. PY - 2009 DA - 2009// TI - Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy JO - Cancer VL - 115 UR - https://doi.org/10.1002/cncr.24064 DO - 10.1002/cncr.24064 ID - Choueiri2009 ER - TY - JOUR AU - Kyprianou, N. AU - Martikainen, P. AU - Davis, L. AU - English, H. F. AU - Isaacs, J. T. PY - 1991 DA - 1991// TI - Programmed cell death as a new target for prostatic cancer therapy JO - Cancer Surv VL - 11 ID - Kyprianou1991 ER - TY - JOUR AU - Westin, P. AU - Stattin, P. AU - Damber, J. E. AU - Bergh, A. PY - 1995 DA - 1995// TI - Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors JO - Am J Pathol VL - 146 ID - Westin1995 ER - TY - JOUR AU - Ohlson, N. AU - Wikstrom, P. AU - Stattin, P. AU - Bergh, A. PY - 2005 DA - 2005// TI - Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment JO - Prostate VL - 62 UR - https://doi.org/10.1002/pros.20139 DO - 10.1002/pros.20139 ID - Ohlson2005 ER - TY - JOUR AU - Benaim, E. A. AU - Pace, C. M. AU - Roehrborn, C. G. PY - 2002 DA - 2002// TI - Gleason score predicts androgen independent progression after androgen deprivation therapy JO - Eur Urol VL - 42 UR - https://doi.org/10.1016/S0302-2838(02)00238-5 DO - 10.1016/S0302-2838(02)00238-5 ID - Benaim2002 ER - TY - JOUR AU - Staack, A. AU - Kassis, A. P. AU - Olshen, A. AU - Wang, Y. AU - Wu, D. AU - Carroll, P. R. PY - 2003 DA - 2003// TI - Quantitation of apoptotic activity following castration in human prostatic tissue in vivo JO - Prostate VL - 54 UR - https://doi.org/10.1002/pros.10179 DO - 10.1002/pros.10179 ID - Staack2003 ER -